Voloridge Investment Management LLC Takes $721,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)

Voloridge Investment Management LLC bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 28,041 shares of the company's stock, valued at approximately $721,000.

A number of other large investors have also recently modified their holdings of NAMS. National Bank of Canada FI bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at approximately $80,000. KLP Kapitalforvaltning AS bought a new stake in shares of NewAmsterdam Pharma during the 4th quarter valued at approximately $154,000. The Manufacturers Life Insurance Company acquired a new position in NewAmsterdam Pharma during the 4th quarter worth approximately $221,000. Finally, Keybank National Association OH bought a new position in NewAmsterdam Pharma in the 4th quarter valued at approximately $257,000. Institutional investors and hedge funds own 89.89% of the company's stock.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The shares were bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the purchase, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. This trade represents a 0.04% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares of the company's stock, valued at $305,550. This represents a 90.91% decrease in their position. The disclosure for this sale can be found here. Insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS traded up $0.48 on Friday, reaching $18.11. The company had a trading volume of 1,010,444 shares, compared to its average volume of 646,091. The firm has a market cap of $1.99 billion, a price-to-earnings ratio of -9.63 and a beta of 0.01. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The business has a 50 day moving average of $17.96 and a two-hundred day moving average of $21.03.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. As a group, research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on NAMS shares. Needham & Company LLC lowered their price target on shares of NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Friday. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Scotiabank boosted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $43.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.